The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
27 May 2022
Historique:
received: 30 04 2022
revised: 24 05 2022
accepted: 25 05 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

IDH (isocitrate dehydrogenase) mutation, hypoxia, and neo-angiogenesis, three hallmarks of diffuse gliomas, modulate the expression of small non-coding RNAs (miRNA). In this paper, we tested whether pro-angiogenic and/or pro-hypoxic miRNAs could be used to monitor patients with glioma. The miRNAs were extracted from tumoral surgical specimens embedded in the paraffin of 97 patients with diffuse gliomas and, for 7 patients, from a blood sample too. The expression of 10 pro-angiogenic and/or pro-hypoxic miRNAs was assayed by qRT-PCR and normalized to the miRNA expression of non-tumoral brain tissues. We confirmed in vitro that IDH in hypoxia (1% O

Identifiants

pubmed: 35682718
pii: ijms23116042
doi: 10.3390/ijms23116042
pmc: PMC9181142
pii:
doi:

Substances chimiques

MicroRNAs 0
Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : APRI from the at the Caen University Hospital center
ID : 2012
Organisme : Ligue Nationale Contre le Cancer
ID : 2012

Références

Mol Cancer. 2014 Feb 21;13:33
pubmed: 24555688
Med Sci Monit. 2014 Dec 07;20:2571-7
pubmed: 25481483
Dis Markers. 2012;32(4):221-30
pubmed: 22430188
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311
pubmed: 28592714
Lab Invest. 2021 Jan;101(1):104-115
pubmed: 32873879
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
J Clin Invest. 2010 Nov;120(11):4141-54
pubmed: 20972335
Int J Mol Med. 2019 Feb;43(2):657-670
pubmed: 30483765
Oncogene. 2012 Feb 16;31(7):858-68
pubmed: 21743492
Biomed Res Int. 2014;2014:198697
pubmed: 24895549
Brain Tumor Pathol. 2018 Apr;35(2):71-80
pubmed: 29470683
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):593-598
pubmed: 32212783
Neuro Oncol. 2012 Sep;14(9):1153-62
pubmed: 22844109
J Biol Chem. 2009 Dec 11;284(50):35134-43
pubmed: 19826008
Exp Mol Pathol. 2020 Dec;117:104550
pubmed: 33010295
Anticancer Res. 2016 Dec;36(12):6691-6697
pubmed: 27920004
Curr Opin Genet Dev. 2005 Oct;15(5):563-8
pubmed: 16099643
Cancer Biomark. 2019;24(1):43-49
pubmed: 30530966
J Neurooncol. 2017 Apr;132(2):207-218
pubmed: 28091987
Acta Neuropathol. 2009 Jun;117(6):599-611
pubmed: 19343354
Br J Cancer. 2020 May;122(11):1580-1589
pubmed: 32291392
Mol Cells. 2011 Jul;32(1):77-82
pubmed: 21544626
Oncol Lett. 2015 Nov;10(5):3183-3190
pubmed: 26722309
Neuro Oncol. 2012 Jun;14(6):689-700
pubmed: 22492962
Biosci Rep. 2020 Jul 31;40(7):
pubmed: 32639004
Biomed Res Int. 2019 Mar 26;2019:4015969
pubmed: 31032345
Sci Rep. 2020 Mar 27;10(1):5644
pubmed: 32221351
Sci Rep. 2019 Jun 24;9(1):9169
pubmed: 31235820
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Oncol Rep. 2017 Jul;38(1):167-174
pubmed: 28534976
J Cell Mol Med. 2012 Oct;16(10):2413-21
pubmed: 22360314
J Neuropathol Exp Neurol. 2017 Apr 1;76(4):246-254
pubmed: 28431179
Onco Targets Ther. 2015 Nov 17;8:3391-400
pubmed: 26604796
J Mol Diagn. 2019 Jul;21(4):695-704
pubmed: 31055025
Front Neurol. 2021 Feb 01;11:610163
pubmed: 33597912
Cancer Cell. 2015 Jul 13;28(1):9-11
pubmed: 26175411
Int J Oncol. 2017 Jun;50(6):1989-1999
pubmed: 28440461
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Pharmacol Sin. 2017 Jan;38(1):110-119
pubmed: 27641735
Biomedicines. 2022 Mar 30;10(4):
pubmed: 35453557
Mol Neurobiol. 2011 Dec;44(3):235-49
pubmed: 21728042
Cancers (Basel). 2017 Jul 10;9(7):
pubmed: 28698530
Circ Res. 2011 Sep 30;109(8):894-906
pubmed: 21868695
PLoS One. 2017 Mar 21;12(3):e0173890
pubmed: 28323865
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Clin Cancer Res. 2010 Mar 1;16(5):1597-604
pubmed: 20160062
Oncogene. 2012 Apr 12;31(15):1884-95
pubmed: 21874051
Oncotarget. 2014 Dec 30;5(24):12908-15
pubmed: 25415048
Oncotarget. 2014 Feb 28;5(4):872-81
pubmed: 24657911

Auteurs

Guénaëlle Levallet (G)

Normandie University, UNICAEN, CNRS, ISTCT Unit, GIP CYCERON, F-14074 Caen, France.
Department of Pathology, CHU de Caen, F-14033 Caen, France.

Fatéméh Dubois (F)

Normandie University, UNICAEN, CNRS, ISTCT Unit, GIP CYCERON, F-14074 Caen, France.
Department of Pathology, CHU de Caen, F-14033 Caen, France.

Arthur Leclerc (A)

Department of Neurosurgery, CHU de Caen, F-14033 Caen, France.

Edwige Petit (E)

Normandie University, UNICAEN, CNRS, ISTCT Unit, GIP CYCERON, F-14074 Caen, France.

Lien Bekaert (L)

Department of Neurosurgery, CHU de Caen, F-14033 Caen, France.

Maxime Faisant (M)

Department of Pathology, CHU de Caen, F-14033 Caen, France.

Christian Creveuil (C)

Biomedical Research Unit, CHU de Caen, F-14033 Caen, France.

Evelyne Emery (E)

Department of Neurosurgery, CHU de Caen, F-14033 Caen, France.

Gérard Zalcman (G)

Department of Thoracic Oncology & CIC1425, Paris Cité University, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, F-75877 Paris, France.
U830 INSERM "Cancer, Heterogeneity Instability and Plasticity (CHIP), STRESS Group", Curie Institute Research Center, F-75005 Paris, France.

Emmanuèle Lechapt-Zalcman (E)

Normandie University, UNICAEN, CNRS, ISTCT Unit, GIP CYCERON, F-14074 Caen, France.
Department of Pathology, CHU de Caen, F-14033 Caen, France.
Department of Pathology, GHU AP-HP University Hospital Henri-Mondor, F-94010 Creteil, France.
INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, F-94010 Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH